


Performance at 31 July 2025

	1 Month	3 Months	6 Months	1 Year	3 Years p.a.	5 Years p.a.	Since Inception p.a.
Fairlight Global Small & Mid Cap Fund	-1.1%	3.6%	-0.9%	6.6%	14.4%	11.8%	12.5%
MSCI World Small & Mid Cap Index	2.8%	10.4%	2.7%	13.0%	13.4%	12.9%	10.5%
Outperformance	-3.9%	-6.9%	-3.6%	-6.4%	1.0%	-1.1%	2.0%

Performance is in AUD and net of all fees. Inception 1 November 2018. Since inception returns are on a per annum basis. Past performance is not an indicator of future performance.


Performance Since Inception



Top 5 Holdings in Alphabetical Order

Company	Region	Sector
Auto Trader Group	GB	Online Marketplace
Diploma	GB	Industrials
Halma	GB	Industrials
Reply	IT	IT Consulting
Scout24	DE	Online Marketplace


Portfolio Sector Exposure



Contact Us E: hello@fairlightam.com.au W: fairlightam.com.au

Portfolio Revenue Exposure

- North America: 50%
- Europe: 38%
- Asia Pacific: 7%
- Africa & Middle East: 2%
- Latin America: 1%



About Fairlight

Fairlight Asset Management is a boutique firm investing exclusively in global equity markets. The investment approach is grounded in fundamental research, long term in nature and has a strong focus on quality. The team believe a portfolio of the highest quality businesses, purchased with valuation discipline will outperform over the long term whilst protecting and preserving client capital.

Investment Philosophy

Fairlight's investment process is designed to find businesses that have a demonstrable track record of earning outsized returns on capital with characteristics that will allow these returns to persist into the future, available at attractive valuations. Where possible, the strategy mitigates potential risk by looking for stable and aligned management teams, conservative balance sheets and avoiding single points of failure.

The portfolio is segmented into three types of investment opportunities:

- High quality growth companies
- Stable compounders
- Special situations

Fairlight does not invest in sectors of the market that do not meet its quality criteria including cyclical business (commodities and mining) and interest rate sensitive businesses (banks and utilities).

Invest Online

Figures and graphs sourced from Apex Fund Services and FactSet Portfolio Analytics. This report has been prepared and issued by Fairlight Asset Management Pty Ltd ACN 628 533 308 Corporate Authorised Representative No 001277649 of AFSL No 000247293, the investment manager of Fairlight Asset Management Global Small and Mid Cap Fund. The Product Disclosure Statement (PDS) contains all of the details of the offer. You can obtain a copy of the PDS and target market determination from fairlightam.com.au or by contacting Fairlight Asset Management directly. Before making any decision to make or hold any investment in the Fund you should consider the PDS and TMD in full. The information provided does not take into account your investment objectives, financial situation or particular needs and is not intended to constitute advice of any kind. Past performance is not an indicator of future performance. Returns are not guaranteed and so the value of an investment may rise or fall. The Trust Company (RE Services) Limited (ABN 45 003 278 831 AFS Licence 235150) is the Responsible Entity of Fairlight Global Small & Mid Cap Fund ARSN 629 066 913.

Medpace powering biotech innovation

The biopharma market is large and growing, benefiting from multiple durable growth drivers including improved diagnosis of medical conditions, longer human life spans and prevalence of age-related diseases. Penetration of medical treatments is rapidly growing whilst the biotech companies responsible for making drug discoveries face increasingly complex regulations and testing requirements prior to commercialisation. Contract Research Organisations (CROs) are companies that offer biotech's outsourced expertise in successfully navigating and completing clinical trials.

Earlier in the year, Fairlight invested in Medpace, a US-based CRO, focused on developing and operating clinical trials primarily for small biotech clients. While at first glance the business of clinical testing may sound complex, Medpace meets Fairlight's quality criteria. The company holds a dominant position in an attractive and structurally growing niche market and delivered strong financial outcomes to shareholders for many years.

Biotech funding across the sector has suffered from macro uncertainty and generally been normalising following several boom years during the COVID pandemic. This has slowed Medpace's growth in recent quarters to a rate that is below the company's 17% p.a long-term average. We believe the long-term growth prospects of the business remain intact.

A specialist, niche leader

Medpace has built significant knowhow and scale advantages over the past 30 years by establishing a network of 40 global offices and conducting thousands of trials across multiple therapeutic areas. Medpace is now uniquely positioned as a full-service, global CRO, managing all aspects of a clinical trial, and in particular, for small to medium sized biotech. Trials are complicated endeavors and can span multiple years while costing billions of dollars. Typically, smaller biotech businesses are under-resourced and the outcome of a single trial can be the difference between having a successful business or shutting down operations. Clearly, it makes sense to outsource this mission critical work to a specialist like Medpace.

Growing and fragmented market

Medpace's core customer base of small and highly innovative organisations, is growing faster than the broader market, at a high single-digit to low double-digit percent growth rate on average. These smaller companies are responsible for generating the lion's share of drug discovery, a share that has been steadily growing for decades. While large CRO competitors have high customer concentration across large pharma companies, approximately 80% of Medpace revenue is exposed to these small biotech, a segment containing thousands of companies. Medpace has only a 5% market share and therefore a long runway to grow alongside its existing clients and gain market share.

Superior execution

When pitching for new business, Medpace consistently delivers an industry leading win rate. Medpace's employee retention is higher than the industry average as most staff are hired directly out of college and then trained by senior management throughout their careers. Longevity of the workforce is an important source of competitive advantage as teams who have a long history of working together tend to be more efficient and experience a higher success rate when conducting clinical trials. This track record can then be used to provide evidence that Medpace is the best CRO to partner with.

Medpace has also been managing risk better than peers. While smaller and early-stage biotech clients may signal higher risk, Medpace is renowned for conducting a more rigorous due diligence process than its peers before accepting a potential client. The company recently "fired" clients they believed to have deteriorating financial health, yet some of the same clients were later accepted by competing CROs. Stricter financial hurdles and a fast payment cycle have resulted in a history of zero bad debts while Medpace itself also has no financial debt.

Strong financials

Medpace has a history of delivering consistently positive organic revenue growth, even during the Global Financial Crisis of 2008 (see Figure 1). Organisational scale, higher productivity and low employee turnover have contributed to industry leading EBIT margins above 20%.

Medpace has low capital requirements, consistently converting 100% of profits into free cash flow, which it has historically returned to shareholders via buybacks. Notably, the company has opportunistically repurchased 7% of its shares over the first 6 months of 2025.

The Fairlight View

Medpace has a superior track record of strong double-digit earnings growth, a differentiated business model and exposure to end markets with long-term structural growth tailwinds. Over the past year, Medpace's revenue growth has been impacted by a challenged biotech funding environment and investors have been nervous about potential regulatory and political impacts. Fairlight's long-term investment horizon allowed us to take advantage of what we believe to be temporary cyclical concerns, purchasing Medpace on a substantial discount to our valuation.

Figure 1.

